1 CA Daly, B De Stavola and JL Sendon et al., Predicting prognosis in stable angina—results from the Euro heart survey of stable angina: prospective observational study, BMJ 332 (2006), pp. 262–267. Full Text via CrossRef
2 PG Steg, DL Bhatt and PW Wilson et al., One-year cardiovascular event rates in outpatients with atherothrombosis, JAMA 297 (2007), pp. 1197–1206. Full Text via CrossRef
3 RJ Burns, RJ Gibbons and Q Yi et al., The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis, J Am Coll Cardiol 39 (2002), pp. 30–36. Article | PDF (171 K) | View Record in Scopus | Cited By in Scopus (119)
4 TJ Wang, JC Evans, EJ Benjamin, D Levy, EC LeRoy and RS Vasan, Natural history of asymptomatic left ventricular systolic dysfunction in the community, Circulation 108 (2003), pp. 977–982. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (125)
5 WB Kannel, C Kannel, RSJR Paffenbarger and LA Cupples, Heart rate and cardiovascular mortality: the Framingham Study, Am Heart J 113 (1987), pp. 1489–1494. Abstract | PDF (577 K) | View Record in Scopus | Cited By in Scopus (470)
6 K Fox, JS Borer and AJ Camm et al., Resting heart rate in cardiovascular disease, J Am Coll Cardiol 50 (2007), pp. 823–830. Article | PDF (264 K) | View Record in Scopus | Cited By in Scopus (121)
7 I Graham, D Atar and K Borch-Johnsen et al., European guidelines on cardiovascular disease prevention in clinical practice: executive summary, Eur Heart J 28 (2007), pp. 2375–2414. View Record in Scopus | Cited By in Scopus (288)
8 P Palatini and S Julius, Elevated heart rate: A major risk factor for cardiovascular disease, Clin Exp Hypertens 26 (2004), pp. 637–644. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (54)
9 A Diaz, MG Bourassa, MC Guertin and JC Tardif, Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease, Eur Heart J 26 (2005), pp. 967–974. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (183)
10 R Kolloch, UF Legler and A Champion et al., Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST), Eur Heart J 29 (2008), pp. 1327–1334. View Record in Scopus | Cited By in Scopus (41)
11 D DiFrancesco and AJ Camm, Heart rate lowering by specific and selective If current inhibition with ivabradine. A new therapeutic perspective in cardiovascular disease, Drugs 64 (2004), pp. 1757–1765. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (118)
12 R Joannides, N Moore and M Iacob et al., Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise, Br J Clin Pharmacol 61 (2006), pp. 127–137. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (20)
13 M Manz, M Reuter, G Lauck, H Omran and W Jung, A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction, Cardiology 100 (2003), pp. 149–155. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (58)
14 AJ Camm and CP Lau, Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology, Drugs R D 4 (2003), pp. 83–89. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (58)
15 JS Borer, K Fox, P Jaillon and G Lerebours, Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial, Circulation 107 (2003), pp. 817–823. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (212)
16 JC Tardif, I Ford, M Tendera, MG Bourassa and K Fox, Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina, Eur Heart J 26 (2005), pp. 2529–2536. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (174)
17 K Fox, R Ferrari, M Tendera, PG Steg and I Ford, Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular dysfunction: the morBidity-mortality EvAlUation of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) Study, Am Heart J 152 (2006), pp. 860–866. Article | PDF (193 K) | View Record in Scopus | Cited By in Scopus (52)
18 The BEAUTIFUL Study Group, The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population, Cardiology 110 (2008), pp. 271–282.
19 KM Fox and EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators, Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study), Lancet 362 (2003), pp. 782–788. View Record in Scopus | Cited By in Scopus (967)
20 J McMurray, L Kober and M Robertson et al., Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial, J Am Coll Cardiol 45 (2005), pp. 525–530. Article | PDF (105 K) | View Record in Scopus | Cited By in Scopus (99)
21 IONA Study Group, Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial, Lancet 359 (2002), pp. 1269–1275.
22 R Peto, MC Pike and P Armitage et al., Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design, Br J Cancer 34 (1976), pp. 585–612. View Record in Scopus | Cited By in Scopus (531)
23 WE Boden, RA O'Rourke and KK Teo et al., Optimal medical therapy with or without PCI for stable coronary disease, N Engl J Med 356 (2007), pp. 1503–1516. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (721)
24 M Komajda, F Follath and K Swedberg et al., The EuroHeart Failure Survey programme–a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment, Eur Heart J 24 (2003), pp. 464–474. View Record in Scopus | Cited By in Scopus (362)
25 GD Giannoglou, YS Chatzizisis, C Zamboulis, GE Parcharidis, DP Mikhailidis and GE Louridas, Elevated heart rate and atherosclerosis: An overview of the pathogenetic mechanisms, Int J Cardiol 126 (2008), pp. 302–312. Article | PDF (847 K) | View Record in Scopus | Cited By in Scopus (27)
26 UE Heidland and BE Strauer, Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption, Circulation 104 (2001), pp. 1477–1482. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (146)
27 A Hjalmarson, S Goldstein and B Fagerberg et al., Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF), Lancet 353 (1999), pp. 2001–2007. View Record in Scopus | Cited By in Scopus (2646)
28 HJ Dargie, P Lechat and E Erdmann et al., The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial, Lancet 353 (1999), pp. 9–13. View Record in Scopus | Cited By in Scopus (2443)
29 M Packer, AJ Coats and MB Fowler et al., Effect of carvedilol on survival in severe chronic heart failure, N Engl J Med 344 (2001), pp. 1651–1658. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (1487)